Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize ... United States that has historically and is currently offering the [MET IHC] assay for ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor ...

Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in ...

Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing ...

The global immunohistochemistry (IHC) market is experiencing steady growth, with a compound annual growth rate (CAGR) of ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test Guardant Health, Inc. (Nasdaq ...

Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio Analysing a blood sample, a technician in a lab coat using precision diagnostic equipment. Guardant Health, Inc. (NASDAQ ...